Seagen v. Daiichi Sankyo & AstraZeneca: Federal Circuit Appeal Dismissed
Seagen brought a patentability challenge under US10808039B2 — covering monomethylvaline compounds central to antibody-drug conjugate technology — to the Federal Circuit against Daiichi Sankyo and AstraZeneca. The appeal was dismissed without a merits ruling after 552 days, leaving the underlying validity question unresolved by the appellate court.
ADC patent appeal ends without merits ruling at Federal Circuit
Seagen, Inc. filed appeal No. 24-1878 at the United States Court of Appeals for the Federal Circuit on 29 May 2024, challenging patentability determinations relating to US10808039B2. The patent covers monomethylvaline compounds capable of conjugation to ligands — chemistry that sits at the core of antibody-drug conjugate (ADC) payloads. The respondents, Daiichi Sankyo and its commercial partner AstraZeneca Pharmaceuticals, LP, together represent the commercial interests behind Enhertu (trastuzumab deruxtecan), one of the highest-profile ADC products in oncology.
The Federal Circuit dismissed the appeal on 2 December 2025, 552 days after filing. The dismissal is procedural rather than substantive: the court did not issue a ruling on the merits of the patentability dispute. The public record identifies the basis of termination as ‘Appeal Dismissed,’ which typically signals a procedural or jurisdictional bar — or an agreement between the parties — rather than a determination that the patent is valid or invalid.
The 552-day duration before dismissal suggests the appeal progressed through at least some briefing stages before concluding, though the precise trigger for dismissal is not disclosed in the publicly available record. The absence of a merits decision means the patentability of US10808039B2’s claims as applied to ADC conjugation chemistry remains unsettled at the Federal Circuit level. Parties operating in the ADC payload space should monitor any subsequent proceedings at the USPTO or district court level that may revisit these claims.
Filing to Appeal Dismissed in 552 days
552 days — longer than the median Federal Circuit appeal timeline of roughly 12–18 months
Appeal dismissed: what the procedural end means for both parties
A procedural dismissal — no merits adjudication
When a Federal Circuit appeal is dismissed without a merits ruling, the appellate court has not affirmed or reversed the decision below. The dismissal may result from lack of jurisdiction, failure to prosecute, or a voluntary agreement between parties. Here, the public record is silent on the specific trigger. Critically, no binding appellate precedent on the patentability of US10808039B2 was created.
No merits ruling issuedSeagen’s patentability challenge ends without appellate vindication
For Seagen (now part of Pfizer), the dismissal means the Federal Circuit did not rule in its favour on the patentability question. Whether the dismissal reflects a strategic withdrawal, settlement, or procedural defect is unclear from the public record. The patent’s enforceability status remains governed by whatever lower tribunal determination preceded this appeal — not by any new Federal Circuit holding.
No appellate relief obtainedDaiichi Sankyo and AstraZeneca avoid adverse Federal Circuit ruling
The dismissal is commercially favourable for Daiichi Sankyo and AstraZeneca in that no Federal Circuit ruling validates Seagen’s patentability challenge. However, because no merits decision was issued, the respondents cannot point to a court ruling definitively upholding or invalidating the contested claims. The ADC payload freedom-to-operate picture remains legally incomplete.
No adverse ruling on recordADC patent landscape remains contested — no appellate clarity
The ADC sector is characterised by overlapping payload chemistry patents, and this dismissal contributes no clarifying precedent. Companies developing monomethylvaline-based payloads or next-generation ADC linker-payload combinations cannot rely on this outcome to resolve freedom-to-operate questions around US10808039B2. Fresh PTAB petitions or district court proceedings remain the likely path to a merits-based resolution.
Patent landscape unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Seagen, Inc. | Company | Biopharmaceutical company — holder of US10808039B2 covering ADC monomethylvaline compoundsSearch in Eureka ↗ |
| Defendant | Daiichi Sankyo | Individual | Daiichi Sankyo and AstraZeneca Pharmaceuticals — co-developers and commercialisers of Enhertu ADCSearch in Eureka ↗ |
| Co-Defendant | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Plaintiff counsel | Dane Sowers | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Devon Wesley Edwards | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sara Tonnies Horton | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Willkie Farr & Gallagher LLP | Law Firm | Representing Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Zeilberger | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Igor Victor Timofeyev | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Justin Fleischacker | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Lucas L. Kressel | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Preston K. Ratliff , II | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Stephen Blake Kinnaird | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing Daiichi SankyoSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: DISMISSED’ — is a procedural termination, not a merits adjudication. The court made no finding on patentability, invalidity, or claim scope. At the appellate level, a dismissal of this form typically reflects either a jurisdictional defect, failure to comply with procedural requirements, or a voluntary withdrawal by the appellant. The underlying patentability question regarding US10808039B2 therefore remains open, and the dismissal creates no binding precedent that would affect parallel or future proceedings.
US10808039B2 — Monomethylvaline ADC payload compounds
US10808039B2 (application no. US16/507839) protects monomethylvaline compounds capable of conjugation to ligands — a class of cytotoxic payloads used in antibody-drug conjugate (ADC) therapeutics. Monomethylauristatin E (MMAE) and related monomethylvaline derivatives are among the most widely deployed ADC payloads in clinical oncology, enabling targeted delivery of potent cell-killing agents. The patent’s claims, as issued, cover the chemical compositions themselves rather than a specific therapeutic product, which confers broad platform-level scope across multiple ADC programmes.
The strategic importance of US10808039B2 lies in its potential to reach multiple ADC products beyond a single drug. Daiichi Sankyo and AstraZeneca’s Enhertu uses a distinct camptothecin-class payload (DXd), but the dispute’s patentability framing suggests contested claim scope that may extend to or implicate adjacent programmes. As the ADC modality expands into new tumour types and linker-payload architectures, foundational payload composition patents carry compounding risk for the sector. Pfizer’s stewardship of this asset post-acquisition of Seagen materially raises the probability of continued enforcement activity.
Should your ADC programme run an FTO against US10808039B2?
Any team developing monomethylvaline-based ADC payloads — including auristatin derivatives such as MMAE or MMAF — or structurally adjacent cytotoxic compounds intended for ligand conjugation should treat US10808039B2 as a priority FTO target. The patent’s composition-of-matter scope, if upheld, could affect upstream chemistry, linker attachment points, and payload licencing strategies. The absence of a Federal Circuit merits ruling means there is no appellate decision to rely on for clearance.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10808039B2 against your compound structures, identify prior art relevant to validity challenges, and flag prosecution history estoppel that may limit claim scope. Eureka can also monitor for new continuation applications in the same family and track PTAB proceedings targeting these claims — giving R&D and IP teams a continuously updated risk picture for ADC payload development.
Run a freedom-to-operate analysis on US10808039B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ADC and oncology patent appeals
Cases involving ADC payload patentability challenges and Federal Circuit appeals in the oncology and biopharmaceutical sector most relevant to this dispute.
What this case signals for the ADC and oncology patent landscape
A Federal Circuit dismissal without merits leaves the ADC payload IP battleground unresolved — and active monitoring essential.
Procedural dismissals preserve optionality — but not certainty
Neither party can claim a definitive win. Seagen (Pfizer) retains the ability to pursue other enforcement or validity routes; Daiichi Sankyo and AstraZeneca cannot rely on this outcome as a clean bill of health for their ADC payload IP. Competitors should not interpret the dismissal as a resolution of the underlying patentability dispute.
US10808039B2 remains a live IP risk for ADC developers
Monomethylvaline compounds are foundational to a broad class of ADC payloads. Because the Federal Circuit issued no merits ruling, the patent’s claim scope has not been judicially narrowed or invalidated at the appellate level. Any company developing auristatin-class or structurally adjacent ADC payloads should treat this patent as requiring active FTO assessment.
Seagen v Daiichi — key questions answered
The Federal Circuit dismissed the appeal on 2 December 2025 without issuing a merits ruling. The basis of termination is recorded as ‘Appeal Dismissed.’ No determination was made on the patentability of US10808039B2, meaning the underlying validity dispute was not resolved at the appellate level.
US10808039B2 covers monomethylvaline compounds capable of conjugation to ligands — a class of cytotoxic payloads central to antibody-drug conjugate therapeutics. Monomethylauristatin derivatives are among the most widely used ADC payloads in clinical oncology. Composition-of-matter claims of this breadth can affect multiple ADC programmes across different companies, making the patent strategically significant beyond any single product.
No. Because the dismissal was procedural and no merits ruling was issued, the Federal Circuit made no finding on patentability or claim validity. The patent’s legal status is governed by whatever lower-tribunal determination preceded the appeal. The dismissal does not constitute a finding that the patent is valid or invalid.
Daiichi Sankyo is the originator of the ADC technology at issue, and AstraZeneca Pharmaceuticals, LP is its commercial co-development and commercialisation partner, including for Enhertu (trastuzumab deruxtecan). Both entities hold commercial interests affected by patentability determinations relating to ADC compound claims, which explains their joint appearance as respondents in the appeal.
The public record does not disclose the reason for dismissal or any settlement terms. Potential next steps could include new PTAB inter partes review proceedings, district court declaratory judgment actions, or a renewed appellate challenge if procedural defects are cured. Pfizer’s acquisition of Seagen suggests continued enforcement interest, but no confirmed follow-on proceedings are evident from publicly available information at this time.
PatSnap Eureka searches patents and litigation data to answer instantly.